<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01681693</url>
  </required_header>
  <id_info>
    <org_study_id>6113</org_study_id>
    <nct_id>NCT01681693</nct_id>
  </id_info>
  <brief_title>Effect of Genetic Variants in MATE1 and OCT3 on the Pharmacodynamics of Metformin in African Americans</brief_title>
  <acronym>#6113</acronym>
  <official_title>Effect of Genetic Variants in MATE1 and OCT3 Transporters on the Pharmacodynamics of Metformin in African Americans With Type II Diabetes Mellitus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study is part of a large multi-investigator grant to look at the pharmacogenetics&#xD;
      of a number of membrane transporters. The investigators will study individuals with&#xD;
      particular genotypes of the human organic cation transporter, (hOCT3), and the multidrug and&#xD;
      toxin extrusion transporter, MATE1 to test the hypothesis that genetic variation in hOCT3 and&#xD;
      hMATE1 are associated with variation in the pharmacokinetics and/or pharmacodynamics of the&#xD;
      antidiabetic agent, metformin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate the potential association of polymorphic genetic variants MATE1 and OCT3 with&#xD;
      altered response to metformin, a genotype to phenotype strategy is employed. Specifically,&#xD;
      the investigators will evaluate this hypothesis in African-Americans, a population which has&#xD;
      a high incidence of type 2 diabetes and which has high variant allele frequencies (44.5% for&#xD;
      MATE1-66T&gt;C and 11.3% in OCT3-81G&gt;delGA) relative to other ethic groups. To assess the&#xD;
      effects of these variants on metformin response, the investigators will measure metformin&#xD;
      renal clearance (pharmacokinetics of metformin), and plasma glucose and insulin levels&#xD;
      (pharmacodynamic response) in healthy and diabetic patients who carry either the reference or&#xD;
      variant alleles.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal Clearance of the Metformin</measure>
    <time_frame>24 hours post-dose</time_frame>
    <description>To test whether individuals with genetic variants of transporters OCT3 and MATE1 exhibit altered pharmacokinetics of metformin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma glucose</measure>
    <time_frame>0, 15, 30, 45, 60, 90, 120, 180 minutes after glucose administration</time_frame>
    <description>To test whether individuals with genetic variants of transporters OCT3 and MATE1 exhibit altered glucose lowering response to metformin.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Healthy</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be given an oral dose of metformin once per day for two days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Subjects will be given an oral dose of metformin once per day for two days.</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>GLUCOPHAGE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects self-identify racial background, identify themselves, parents and four&#xD;
             grandparents as African American&#xD;
&#xD;
          -  Subject status is healthy volunteer from t In the event that diabetes is indicated in&#xD;
             a normal subject based on OGTT results, we will notify the patients' primary care&#xD;
             physician. he SOPHIE cohort OR diagnosis of T2DM based on American Diabetes&#xD;
             Association (ADA) criteria&#xD;
&#xD;
          -  Subjects over 18 years old and below 60 years&#xD;
&#xD;
          -  Subjects who are healthy on the basis of medical history, physical examinations and&#xD;
             laboratory tests if healthy volunteer from SOPHIE&#xD;
&#xD;
          -  Subjects who agree with the written informed consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to confirm African-American ethnicity&#xD;
&#xD;
          -  Under 18 years old&#xD;
&#xD;
          -  Pregnant or lactating women (female subjects will have a urine pregnancy test at the&#xD;
             screening visit).&#xD;
&#xD;
          -  Prior history of any allergic reaction to metformin&#xD;
&#xD;
          -  Has a risk of congestive heart failure requiring pharmacologic treatment (medical&#xD;
             history)&#xD;
&#xD;
          -  Has a prior history of renal* or hepatic dysfunction (renal and hepatic function will&#xD;
             be evaluated based on screening blood tests conducted prior to study enrollment)&#xD;
&#xD;
          -  Risk of urinary or gastric retention or narrow-angle glaucoma (by medical history&#xD;
             examination)&#xD;
&#xD;
          -  Impaired renal function (e.g as suggested by abnormal creatinine clearance, eGFR &lt;60&#xD;
             or serum creatinine &gt;1.4 mg/dl in females and &gt;1.5 mg/dl in males) which may also&#xD;
             result from conditions such as cardiovascular collapse (shock), acute myocardial&#xD;
             infarction (heart attack), and septicemia, abnormal heart rhythms (tachyarrhythmias;&#xD;
             heart beat &gt; 100 beats per minute).&#xD;
&#xD;
          -  Impaired hepatic function (&gt; 1.5 times the upper limit of normal)&#xD;
&#xD;
          -  Evidence of anemia (hemoglobin &lt;10 g)&#xD;
&#xD;
          -  Taking a medication that could confound study results, such as known substrates or&#xD;
             inhibitors of OCT3 and MATE1, such as cimetidine.&#xD;
&#xD;
          -  They do not provide consent to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen M Giacomini, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco General Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>August 1, 2012</study_first_submitted>
  <study_first_submitted_qc>September 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2012</study_first_posted>
  <last_update_submitted>October 21, 2014</last_update_submitted>
  <last_update_submitted_qc>October 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

